Treatment of neuroendocrine tumors by nuclear medicine: a systematic review of efficacy and safety of the radiopharmaceutical 177Lu-DOTATATE
Keywords:
Neuroendocrine tumors, 177Lu-DOTATAT E, efficacy, safety, lutetium-177.Abstract
The DOTATAT E-177Lu is a radiolabeled somatostatin analogue that guides the radioactivity to neuroendocrine tumors (NETs) that overexpress somatostatin receptors (SSTRs), allowing their treatment by receptor- specific radionuclide therapy (PRRT). The aim of this study was to evaluate the efficacy and safety of PRRT of NETs with DOTATAT E-177Lu through a systematic literature review. PRRT with 177Lu - DOTATAT E was effective in the treatment of inoperable or metastatic NETs that express SSTR type 2. Stabilization or regression of the disease was observed in 20 to 50% of the cases . The prevalence of total remission, although numerically low, was satisfactory, especially taking into account the advanced tumor stage. The most common adverse events in the PRRT were hematological toxicity and renal failure. Despite studies demonstrate the efficacy and safety of PRRT with the radiotracer , this treatment modality is still considered under development.
Downloads
Downloads
Published
Issue
Section
License
Autores que publicam nesta revista concordam com os seguintes termos:- Autores mantém os direitos autorais e concedem à revista o direito de primeira publicação, com o trabalho simultaneamente licenciado sob a Creative Commons Attribution License que permitindo o compartilhamento do trabalho com reconhecimento da autoria do trabalho e publicação inicial nesta revista.
- Autores têm permissão e são estimulados a citar e distribuir seu trabalho (ex.: em repositórios institucionais, página pessoal, trabalhos científicos, etc) desde que citada a fonte (referência), já que isso pode gerar produtividade para os autores, bem como aumentar o impacto e a citação do trabalho publicado.
